PMID- 14747902
OWN - NLM
STAT- MEDLINE
DCOM- 20041122
LR  - 20181113
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 173
IP  - 3-4
DP  - 2004 May
TI  - MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine 
      transporter knockout mice.
PG  - 310-7
AB  - RATIONALE: Mice lacking the gene for the dopamine transporter (DAT) show a unique 
      behavioral phenotype characterized by locomotor hyperactivity and repetitive 
      circling in a novel environment. The hyperactivity of DAT (-/-) mice can be 
      attenuated by psychostimulants and by serotonin uptake inhibitors, suggesting an 
      important role for serotonin in the attenuation of locomotor hyperactivity in 
      these mice. OBJECTIVES: These studies characterized the effects of 
      3,4-methylenedioxy-N-methylamphetamine (MDMA), a serotonin releaser, on the 
      amount and patterns of locomotor activity in DAT (+/+) and (-/-) mice. We 
      compared the locomotor patterns produced by MDMA to those observed in DAT (-/-) 
      mice, and examined whether MDMA altered the hyperactivity and perseverative 
      locomotor patterns in DAT (-/-) mice. METHODS: The effects of MDMA (10, 30 mg/kg) 
      on locomotor activity in DAT (+/+) mice were measured for 90 min in a video 
      tracker system to determine the optimal dose for subsequent studies in DAT (+/+) 
      and (-/-) mice. The effects of 20 mg/kg MDMA on patterns of locomotor activity in 
      DAT (+/+) and (-/-) mice were measured for 90 min. RESULTS: In DAT (+/+) mice, 
      MDMA increased locomotor activity and induced repetitive straight movement 
      patterns. In DAT (-/-) mice, however, MDMA (20 mg/kg) attenuated the 
      characteristic locomotor hyperactivity seen in these mice. In contrast, MDMA 
      potentiated the thigmotaxis and decreased entropy observed in the DAT (-/-) mice. 
      CONCLUSIONS: The effects of MDMA observed here demonstrate that the different 
      aspects of the abnormal locomotor behavior exhibited by DAT (-/-) mice can be 
      independently manipulated by pharmacological treatments.
FAU - Powell, Susan B
AU  - Powell SB
AD  - Department of Psychiatry 0804, University of California San Diego, 9500 Gilman 
      Drive, La Jolla, CA 92093, USA.
FAU - Lehmann-Masten, Virginia D
AU  - Lehmann-Masten VD
FAU - Paulus, Martin P
AU  - Paulus MP
FAU - Gainetdinov, Raul R
AU  - Gainetdinov RR
FAU - Caron, Marc G
AU  - Caron MG
FAU - Geyer, Mark A
AU  - Geyer MA
LA  - eng
GR  - DA02925/DA/NIDA NIH HHS/United States
GR  - DA14200/DA/NIDA NIH HHS/United States
GR  - MH60451/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20040128
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Serotonin Agents)
RN  - 0 (Slc6a3 protein, mouse)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Central Nervous System Stimulants/*pharmacology
MH  - Dopamine/*metabolism
MH  - Dopamine Plasma Membrane Transport Proteins
MH  - Female
MH  - Male
MH  - Membrane Glycoproteins/*deficiency/genetics
MH  - Membrane Transport Proteins/*deficiency/genetics
MH  - Mice
MH  - Mice, Knockout
MH  - Motor Activity/*drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nerve Tissue Proteins/*deficiency/genetics
MH  - Serotonin Agents/*pharmacology
EDAT- 2004/01/30 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/01/30 05:00
PHST- 2003/12/07 00:00 [received]
PHST- 2003/12/11 00:00 [accepted]
PHST- 2004/01/30 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/01/30 05:00 [entrez]
AID - 10.1007/s00213-003-1765-7 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2004 May;173(3-4):310-7. doi: 
      10.1007/s00213-003-1765-7. Epub 2004 Jan 28.